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4 
 
 Introduction   
 
 New survey instruments are generated every day with documentation that reports their 
psychometric properties, such as Reliability, Effect Size and Responsiveness.  These statistics  
may be used to choose among valid instruments whose content measures what the researcher 
intends to measure.  (In the following we shall sometimes refer to these three characteristics 
jointly as “Reliability” for short, since they will all be seen to be related).  Another property, 
relevant for cluster-randomized trials, is the Intraclass Correlation (ICC) among persons within a 
cluster.  Reliable instruments can reduce the necessary sample size, but there are settings where 
the most reliable instrument is too “expensive” for the projected use.  
 The cost of using a particular instrument may be thought of in  terms of time (patient or 
interviewer time), length (space required on a survey designed to examine multiple facets of 
health, and the related opportunity cost of not measuring the other facets as well), or dollars 
(costs of  proprietary instruments,  highly trained interviewers or interpreters), and the accuracy 
of the resulting data (lower response rates or accuracy due to increased patient burden).  
 The best instrument is one that fits the study needs, but is not necessarily the most 
reliable instrument.   An instrument used to diagnose, treat or refer an individual should have 
high Reliability; Nunnally suggests that a value of .90 be used.1 However, most research 
involves the comparison of groups of persons, often on their mean score. It is well known, 2  but 
perhaps less well understood, that less reliable instruments can have high power to detect 
difference in the means of two groups, if the sample size per group is high enough.  For example, 
a Reliability of .70 has been recommended as a minimum Reliability to be used in comparing 
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two groups. 1, 13,  3   
 Behavior change interventions are often conducted as cluster-randomized trials when the 
intervention naturally occurs at the cluster level. 4 5  6 7 8 9 10 11   In this situation, the study design 
requires choosing the number of clusters per treatment and the number of persons to survey per 
cluster, as well as which instrument to use.  There has been, to our knowledge, no discussion of 
how to choose the best instrument for a cluster-randomized trial. 
 The purpose of this paper is to define a statistical model to define the psychometric 
statistics, to show how they are related to one another, to show how they are related to the power 
and necessary sample size of a study, and to discuss the data needed to estimate them accurately.  
In addition, we develop approximate equations to calculate the sample size needed to assess the 
Reliability (etc.) of new psychometric instruments. 
 Methods 
 We begin this paper with a review of several psychometric statistics, starting first with a 
statistical model for the true values, and then introducing the usual  “true value plus error” model 
for an instrument. We begin at the person level and then consider randomized trials and cluster-
randomized clinical trials.  We use a combination of exact calculations, simulation, and real data 
to describe the psychometric properties.  For the simulations we generated data described by the 
model in Table 1, with varying values of SD (1,2,5,10) and N per treatment group (10, 20, 50, 
100, 250, 500, 1000), with 151 replicates for each set of parameters.  For each combination of N 
and SD we estimated Delta,  Reliability, Effect Size, and Responsiveness  (defined below) from 
each sample.  We calculated the standard error of the 151 estimates.   We found from exploratory 
analyses that the logarithm of the sample size was linearly related to the other parameters,  and 
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so regressed the log of the sample size on the standard error  and the true value of the parameter.  
We used the resulting equation to estimate the sample size needed to estimate each psychometric 
statistic to a given level of precision.  This is explained more detail in the section under 
Reliability, below. 
 
 True State 
 Consider a construct, perhaps a person’s true health, denoted as Z, and described  in 
Table 1, where a higher value denotes better health.   For this example, Z is assumed to be 
normally distributed in the population, with µz = 50 and sz =10.  We will consider three time 
points, T0, T1, and T2, where.   T0  and T1 are “close together” (perhaps a week apart) and T2 is 
perhaps a year later.   The true values of Z (health) for those times will be denoted Z0, Z1, and Z2.     
T0 and T1 are close enough together that health has not changed (Z0=Z1).  From T1 to T2 there is 
some natural change (secular trend) over time, which is normally distributed with mean µtrend =  1 
and standard deviation strend = 1.  Half of the people will thus improve 1 or more points, and half 
will improve less; in fact, 16% will be sicker at T2 than they were at T1.   Finally,  half of the 
hypothetical people are assigned to an experimental treatment which raises each person’s Z value 
exactly 3 points at T2.  The true change from T1 to T2 is the secular trend (mean 1, standard 
deviation 1) plus the treatment effect (3).   Z2 thus has mean 54 in the treatment group and 51 in 
the control group, and in both groups the variance is 101 (because it includes the variance of  the 
secular change). 
 [Table 1 about here] 
 Although different parameter values could have been chosen for the true situation, our 
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interest is only in how well a particular instrument measures truth.   The bottom half of Table 1 
deals with an instrument that estimates Z, with some error.  We refer to the value from the 
instrument as Y.  Y (given Z) is equal to the true value of Z plus error, where the error has mean 
M and standard deviation SD, and M is independent of Z.  If M is zero, then Y is an unbiased 
estimate of Z.  We will let M equal zero, without loss of generalizability, since the psychometric 
measures we will discuss all remove the mean. In the following we will consider the 
characteristics of Z as fixed, but will examine the effect of changing SD.  (We use Greek 
symbols to denote the values that will be held constant).   For future reference, the distributions 
of the Z’s, the Y’s and of the change score Y2 - Y1 are summarized in Table 2.  These 
distributions can be derived from the information in Table 1.  In the following we consider all 
parameters in Table 1 to be fixed except SD, and will examine the effect of varying SD. 
 [Table 2 about here] 
  
Correlations among measures. 
 Some correlations among the various measures are summarized here.  Consider first the 
correlation between Y0 and  Z 0, which we will refer to as ryz. Although these correlations can be 
calculated algebraically, a more mnemonic  way is to recall  that R2yz is the proportion of 
variation in Y that is explained by Z.  From Table 1 and Table 2, it is clear that this proportion is 
s2z /(s2z+ SD2) =100 / (100 + SD2).    If SD is 2.29, then R2yz = .95, and its square root is  ryz = 
.975.  The correlation between Y0 and Y1 (ryy) can be thought about in two parts.  Y0 explains 
R2yz of the variability in Z0 which also, because  Z0 =Z1, explains R2yz of the variability in Y1.  
The percent of variability in Y1 explained by Y0 is then the product of these two percentages, or 
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(R2yz)2, and ryy = R2yz.   These correlations are shown in Table 3, for several values of SD.  
Correlations all decrease as SD increases. 
 [Table 3 about here] 
 
 Psychometric Characteristics of the Instrument Y 
 Three commonly cited properties of an instrument are its test-retest Reliability, Effect 
Size, and Responsiveness. 2, 19 12  13  14 15 16   These will be discussed in turn.   Another property, 
Intraclass Correlation within clusters, is discussed in the section on cluster-randomized trials. 
 Reliability.  Reliability is a measure of whether the same person, under the same 
conditions, would give the same response.  It is usually estimated from test-retest data (ideally 
two measures taken close enough in time that the true value has not changed, but far enough 
apart that the previous response doesn’t affect the current answer), which are used to estimate the 
intraclass correlation within a person.  We will refer to this intraclass correlation only as 
“Reliability”, to avoid confusion with the Intraclass Correlation within a cluster, discussed under 
cluster-randomized trials.  Reliability is the proportion of the variance among people’s scores  
that is accounted for by their true values.  In our situation Reliability is clearly Var(Z0) /Var(Y0)  
= ryy =s2z / (s2z + SD2) = 100 / (100 + SD2), but ordinarily Reliability must be estimated.  
Although usually defined in terms of analysis of variance, estimates of test-retest reliability can 
be obtained more simply from a paired t-test of the test-retest data, as demonstrated elsewhere. 17  
In our setting, Reliability would be estimated from Y0 and Y1, as follows: 
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Values of the Reliability of Y for selected values of SD are shown in Table 4.  Perfect Reliability 
(1.0) is achieved if SD = 0, and it becomes lower for larger values of SD. 
 [Table 4 about here] 
  We also simulated person-level data (Y’s)  according to the model in Table 1 and 
estimated the psychometric statistics from each sample.   We varied SD and N, the number of 
persons per treatment group, and examined the distributions of the resulting estimates to examine 
the properties of estimated Reliability.  For example, with samples of size 20, where the true 
Reliability was .80, the estimated Reliability ranged from .45 to .95 with a mean of .80 and a 
standard deviation of .09.  The histogram of estimates from this simulation is shown as Figure 1.  
Clearly, Reliability estimates based on a sample of only 20 subjects are likely to be inaccurate. 
 [ Figure 1 about here] 
  To explore this variability we generated 151 such estimates of Reliability for each 
combination of  N (from 20 to 2000), and Reliability (from .5 to .99).   For each set of 
parameters we calculated the standard deviation of the 151 estimates of Reliability (s Reliability), 
which  decreased as either N or the true Reliability increased.  We regressed  ln(N) on true 
Reliability, ln (Reliability), and ln(sReliability).  The fit was excellent (R2= .92)..  From this 
regression, the N needed to achieve a specified accuracy for the estimated Reliability can be 
calculated as:  
 N  = exp[69.4  -1.75*ln(sReliability )  -75.1*Reliability  + 45.6*ln(Reliability) +.6192/2],  
where   .619 is the standard error of the regression, and is included to adjust for the re-
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transformation bias in the lognormal distribution. 18   For example, suppose the instrument is 
expected to have Reliability about .8, and the investigators wish the estimate of Reliability to fall 
between .7 and .9 with 95% probability; that is, the confidence interval will have length 0.20.  
Assuming normality of the estimates, about 95% of the estimated Reliability values will fall in 
the range Reliability + 2* sReliability, meaning that the value of sReliability must be 0.05.   From the 
equation, the required N is 100; that is, about 100 people would be needed for a test-retest study 
to estimate the Reliability to this level of accuracy.  This number would be lower if the true 
Reliability was higher, or if a wider range of confidence was permitted.  For example, if the 
range of 0.6 to 1.0 was permissible, the desired sReliability would be .10, and the required N would 
be 30.  For sReliability  = 0.025, a sample of 336 would be needed.  If there is no information on the 
probable Reliability of a new instrument, it is conservative to assume a smaller value of 
Reliability for this calculation. 
  Delta (∆). The next two psychometric measures (Effect Size and Responsiveness) require 
∆specification of the change in Y in a specific situation, which we shall refer to as ∆.  The 
quantity   ∆ is defined in several different ways.   It may be defined as the minimum clinically 
important difference or change, which is not usually well specified.  19  If  ∆ is defined as the 
change associated with a treatment of known efficacy, it is obvious that ∆ = 3 for our situation, 
since the treatment makes a change of 3 points for each person in the treatment group.  However, 
if we had a different treatment in mind, which changed the treatment group by 10 points, then ∆ 
for that situation would be 10.  Thus, an instrument could have many values of ∆,depending on 
the intervention effect that was assumed.  For practical reasons, ∆ is often estimated from 
available data.    It has been estimated as the mean change over time in a group of patients in the 
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treatment group of an RCT, or in patients who seemed improved by some other standard.17  
Under our model, such an estimate would include the secular trend, and the estimated ∆ would 
be 4 rather than 3.  Others have subtracted the change in the “control” group from the change in 
the “treatment” group, which would provide an estimate of ∆= 3.  20 It is important to specify the 
source of the ∆ used in calculations. 
 Effect Size (ES).  Although Effect Size has many definitions, 21 the most common 
estimate of ES is ∆ divided by the standard deviation of the “before” value for a particular 
instrument, with a particular value of SD.  Under our model this would be: 
222
1 100
3
SDSD
ES
ZY +
=+
∆=∆= σσ  
For SD=0, ES = 0.3,  and ES approaches zero as SD becomes larger.  Values of ES are shown in 
Table 4 for different values of SD.  
 We used the simulated data to explore the variability of the estimated Effect Size as 
explained in the Reliability section.  (We estimated ∆ as the difference in change between the 
treatment and control groups). Variability was lower for larger N, and for instruments with larger 
Effect Size.  We regressed  ln(N) on Effect Size, ln(s Effect Size), and ln (Effect Size).  The fit was 
excellent (R2= .996)..   The  N needed to achieve a specified accuracy for the estimated Effect 
Size is:  
 N  = exp[116.2  -1.90*ln(s Effect Size )  -205.5*Effect Size  + 46.1*ln(Effect Size) 
+.1432/2].  
For example, the necessary N if the expected Effect Size = .25 and the desired sd Effect Size is .05 is 
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thus 689 (343 per group); if sd Effect Size = .10, only 92 persons per group are needed.   It is 
conservative to assume a smaller Effect Size. 
 Responsiveness.   Responsiveness is the ability of an instrument to detect minimal 
clinically important differences, which is defined as the expected change in Y under a treatment 
of known efficacy divided by the standard deviation of change in stable subjects. 19   Under our 
model, the stable subjects are the controls, and  
 
 
Values of Responsiveness for different values of SD are in Table 4.  The highest possible 
Responsiveness, when SD = 0, is ∆ = 3.0.  
 In the simulated data, the estimates of Responsiveness were less variable for larger N, but 
surprisingly became more variable as Responsiveness increased.  We regressed  ln(N) on 
Responsiveness, ln(s Responsiveness), and ln (Responsiveness).   The fit was excellent (R2= .994)..   
We used the regression equation to calculate for the N needed to achieve a specified accuracy for 
the estimated Responsiveness, with results as follows:  
N  = exp[-0.354  -1.870*ln(s Respons ) +1.479*Respons  - 0.354*ln(Respons) +0.1612/2].  
The necessary N if the expected Responsiveness= 1.0 and the desired sd Respons= .05 would be 
846 (423 per group); for sd Respons = .10, only 116 persons per group would be needed. Unlike 
the other statistics, it is more conservative to assume that Responsiveness is larger. 
 One attractive feature of the Responsiveness statistic  is that it can be used directly to 
Re
* *
sponsiveness
SD SDtrend
= + = +
∆
σ 2 2 22
3
1 2  
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estimate the necessary sample size per group for detecting a difference of ∆ in the treatment and 
control change scores.    For 80% power, for example, N per group = 2* (1.96+.84)2/Respons2.    
The necessary sample sizes per group to achieve 80% power in our hypothetical clinical trial are 
shown in Table 4 for various values of SD.   (The tabled sample size for SD=0, (3.5), is not 
accurate because we used the normal approximation rather than the t-test). 
 Cluster Randomized Trials (CRTs)  
To this point we have compared the means of two groups of persons.  Cluster randomized 
trials (CRTs) are conducted when the intervention is performed at the cluster level, but the 
effects are measured on individuals. 7,8,9, 25, 22   Investigators  must choose both the number of 
clusters (C) to be randomized to treatment or control, and the number of persons per cluster (N) 
to be evaluated, in addition to choosing the instrument to be used in the assessment.  For 
simplicity, we assume that the N persons in each cluster will be evaluated at times T1 and T2, the 
change in the two scores calculated, and the mean change calculated for each cluster.  The 2*C 
cluster means (C for treatment and C for control), will then be analyzed using a t-test.  
(Randomization tests 23  and multi-leveling model are alternative approaches). 
 In the hypothetical CRT, then, the same person-level model applies, but the people were 
assigned to treatment/control by cluster, with N persons per cluster.  We further assume that the 
true mean change  is different in each cluster (independent of any intervention), with the 
differences distributed as Normal (0, σ2C).  That is, the true  mean change is different in each 
community, but the clusters in the treatment group will have an average change 3 points higher 
than the controls.  Intraclass correlation is the correlation among persons within the same cluster.  
The ICC is also the fraction of the total variation in the data that is attributable to the unit of 
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assignment (the cluster—in Murray, page 7, where our clusters are his groups and our treatment 
groups are study conditions). 24   The Intraclass Correlation (within a treatment group) is the 
variance among clusters divided by that variance plus the variation among people within 
clusters:   
222
2
22
2
*2 SD
ICC
trendC
C
changeC
C
CRT ++=+= σσ
σ
σσ
σ
 
ICC CRT  (henceforth referred to simply as ICC) is near to 1 if there is high variability among 
clusters in the mean amount of change, and is smaller if there is a good deal of variability in the 
trend over time.  Table 4 shows some values of ICC assuming that σ2C = 1.0.  As the instrument 
becomes less reliable (SD increases), the ICC decreases  because there is relatively more 
variation within the clusters than among them.  
 Feng and Grizzle provide sample-size formulas for the situation in which the number of 
clusters per group is 10 or greater, parameterized in terms of the ICC. 25 Since we wish to 
consider smaller numbers of clusters, we present different calculations here.  In the following we 
selected values of σ2C to yield nice values of the ICC and also varied  SD, C, and N to determine 
the sample size per cluster needed to obtain 80% power.    This design can be thought of as an 
analysis of variance for a nested design, with clusters nested in treatment and persons nested in 
clusters. The variance of the mean for a treatment group is the variance among persons 
(σ2trend+2SD2) divided by the number of persons (NC) plus the variance among clusters (σ2C ) 
divided by the number of clusters (C).  26     
Var D
C
SD
NC
C trend( ) = + +σ σ2 2 22  
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Since the number of clusters per group is usually small, the number of clusters needed to achieve 
a power of β must be specified in terms of the percentiles of the t-distribution instead of the 
normal distribution.   Following the usual derivation of sample size in the normal case, and 
assuming the variance of D is the same in both treatment groups, we need to find a value of C 
such that under the alternative hypothesis the probability of rejecting the null hypothesis is 1-β, 
when the difference is actually ∆, or 
βα −=>− −− 1)/2Pr( 2/1,22
21
CtCs
DD  
The quantity in parentheses on the left does not have a central t-distribution under the alternative 
hypothesis, but subtracting   
Cs /2
∆  from both sides of the inequality yields 
βα −=∆−>∆−− −− 1)/2/2Pr( 2/1,.22
21
Cs
t
Cs
DD
C  
where the left side does have a central t distribution.  The equality holds only if  
βα ,222/1,.22 /2 −−−
=∆− CC tCst ,   
or the number of clusters per group is 
2
22
1,222/1,22 2)(
∆
+= −−−− sttC CC βα  
Letting T2C-2 be the term in parentheses, and setting s2 to a single community’s variance, i.e.,  C 
times the variance of  D ,  the necessary number of clusters (C) for a fixed value of N is: 
2
2222
22 )/)2((2
∆
++= − NSDTC trendCC σσ  
As T2C-2 is different for different values of C, this equation must be solved iteratively.  We 
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solved instead for the number of persons needed per cluster (N), for a fixed number of clusters 
per treatment group (C).   
22
22
2
222
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)2(2
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trendC
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SDTN σ
σ
−
−
−∆
+=  
Although this does not reduce to a convenient function of the ICC, the sample sizes needed per 
cluster for different values of C and ICC can be calculated, as shown in Table 5.  For example, if 
ICC=.01, Reliability of the instrument= .25, and C = 20 clusters per treatment group, then a 
study with 124 persons per cluster will yield 80% power with alpha=.05, and only 23 persons per 
cluster are needed if the Reliability is .50.   Table 5 shows that higher Reliability, more clusters, 
and lower ICC are all associated with smaller required sample sizes.  There are many different 
configurations of Reliability, C, and N that will allow a trial with 80% power, and these 
configurations are different depending on the ICC of the instrument.    For example, if there are 
only two clusters per treatment group but the ICC is .01 and Reliability is .95, the CRT will have 
80% power with 59 persons per cluster.   Blank cells means that it is not possible to achieve 80% 
power with this configuration.  When the number of clusters is small, a more reliable instrument 
may be needed. 
 [Table 5 about here] 
 Feng and Grizzle found that an asymptotic equation for the variance of estimated ICC 
was accurate for situations with 10 or more clusters and 30 or more persons per cluster. 24  
Because we wanted to study the behavior of estimates of the ICC for smaller numbers of 
clusters,  we created 200 random datasets following the CRT model, and estimated the ICCCRT 
from each dataset.  Murray (p. 81) suggests that an ICC value of .02 is typical. 27   (Campbell et 
Hosted by The Berkeley Electronic Press
  
17 
al report ICC’s for cost data as large as 0.47). 28  For the simulation we considered ICC = .02 and 
.05; SD = 2.29, 5, and 10; and N = 50 and 100.   As there are many possibilities, we present only 
some typical cases.  Suppose the goal is to estimate the ICC to within plus or minus .01 with 
80% probability; (that is, 80% of all estimates will be within + 0.01 of the true ICC).  This can be 
achieved for ICC = .02 and N = 100 with C = 25; for ICC = .02 and N = 50 with C = 40; and for 
ICC = .05 and N = 50 more than 80 clusters are required.  Since the number of available clusters 
(C) is usually much smaller that these calculated values, most published ICC estimates are 
probably inaccurate.  The asymptotic formulas for the variance of the ICC of Feng 24 and Donner 
22 were accurate for 10 or more clusters, but underestimated the variance for 2 and 5 clusters. 
 
 Cost of Using a Particular Instrument 
  The cost of including Quality of Life measures in clinical trials has been considered, 29 
but the cost associated with a particular instrument was not discussed.   Proprietary instruments 
have license fees.   An instrument that requires highly trained professionals to administer and 
interpret it is more expensive, and a more detailed instrument may require more of their time.  If 
the total length of the survey is constrained, use of a particular instrument has opportunity costs, 
in that using a long instrument to measure one patient characteristic could preclude measuring  
different characteristics well or at all.  Other non-monetary costs of a longer instrument include 
subject burden, and the likelihood that subject fatigue will lead to lower quality data. 
 In a randomized clinical trial (RCT) a more reliable instrument would usually be 
preferred because it permits smaller sample sizes, as shown in Table 4.  However, if there were 
large differences between the costs of the most reliable instrument and an alternative, it could be 
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more cost-effective to use the less reliable instrument and achieved the desired power through an 
increase in sample size.   There are many situations in which the sample size is determined based 
on some other criterion.  Many studies are powered to detect mortality differences, which usually 
provides more subjects than needed to detect differences in quality of life.30  Large, simple trials 
are designed especially to study very large numbers of persons, and their success depends on 
using extremely simple data collection instruments. 31  The study’s sponsor may require 
including all  people in a certain class, such as all primary care patients in a clinic.  In those 
cases, the most reliable instrument might not be needed.  For example, if the sample size was 
fixed at 350 per group for some reason, Table 4 shows that an instrument with Reliability of only 
.50 would have sufficient power to detect the difference of interest in our example.  Such a 
choice might reduce respondent burden and other costs.  This also holds true for cluster-
randomized trials. 
 Example: Data from the LIDO Study 
 The Longitudinal Investigation of Depressive Outcomes (LIDO) study was an 
observational study of depression in 6 international cities. 32   Primary care patients who met 
eligibility criteria were assessed for depression using the Composite International Diagnostic 
Interview  (CIDI). 33   There were 981 persons who had clinical depression at baseline and a 
valid CIDI assessment nine months later, which was the “gold-standard” for whether their 
depression had remitted.   Here we use these data at the person level and also use the mean 
change for each of the 6 cities, to illustrate the points made earlier.  We compare the MHI5 
mental health subscale of the SF-36  to the single item (from that scale)  “Have you 
accomplished less than you would like as a result of any emotional problems (such as feeling 
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depressed or anxious)?”   Table 6 shows  information about the two mental health instruments, 
including the sample mean, standard deviation, the estimated Reliability (calculated from the 
baseline and 6 week measures), Effect Size, and Responsiveness.  The 5-item scale had better 
psychometric characteristics than the single item, but the difference was not large.    
 We assumed the marginal cost of using the two instruments was proportional to their 
length, assuming a stem question plus 5 or 1 additional questions, for costs of 6 or 2, 
respectively.  In planning a new study, the necessary sample size per group to achieve 80% 
power is 2*(1.96+.84)2 / Responsiveness2 .  The shorter instrument would require a larger sample 
size, but the total cost (unit cost * sample size)  would be only about half as high for the shorter 
instrument (58 versus 108).  This is an example in which the less reliable instrument might be 
preferred, if it included  the content that was necessary for the investigation at hand.  The 
decision would need to balance these marginal costs with the fixed costs of obtaining an 
additional person. 
 We also estimate s2C from the 6 cities (clusters), and calculated the ICC at baseline, at 9 
months, and for the average change.  The cross-sectional ICC estimates were higher for the 
single item at baseline and 9 months, but the ICC for change was slightly smaller for the single 
item.  Three of the estimates were near .02, and three were substantially higher. Based on the 
simulation results  described above, it is unlikely that the estimated ICC’s are close to the true 
value.    
 
Discussion 
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 We used the usual true score plus error model to describe  a valid instrument that 
measures true health with a certain amount of error.  Under this model, all of the psychometric 
statistics were a function of SD, the measurement error, and so behaved in similar ways.  We 
also noted some inconsistencies in how parameters were defined (particularly ), the true 
treatment effect), which would often restrict the usefulness of the Effect Size and 
Responsiveness estimates in the literature.  An instrument has one Reliability, but may have a 
variety of Responsiveness and Effect Size values, since they depend on ).  Estimates in the 
literature are also sensitive to the values of s2C , s2Z , or s2Trend in the study. 
 Instruments should be chosen to meet the purposes of the investigation.  This does not 
always involve choosing the “best” instrument, which may be too expensive and have features 
that are not needed.  In a clinical trial setting, where the object is to achieve a specified power to 
detect a specified treatment effect, any of the instruments under consideration could be suitable if 
only the sample size were high enough; that is, you can make it up in volume.  If only a few 
subjects are available, a highly reliable instrument can increase the power.   An example using 
data from the LIDO study suggested that a single item might sometimes be chosen in preference 
to a 5-item question on the basis of cost-effectiveness if the costs of finding additional subjects 
are not high.   
 There is little in the literature about the sample sizes needed to estimate the psychometric 
statistics accurately.   Our simulations show that rather large samples are required to provide 
accurate estimates.  Nunnally suggested N = 300 for estimating Reliability, but our results 
suggest that smaller N’s may be sufficient for highly reliable instruments.  Precise estimates of 
Effect Size and Responsiveness will require larger N’s.  We recommend that re-sampling 
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methods such as bootstrap be used when Reliability is estimated, to provide future users with the 
degree of accuracy.  This is easily feasible but rarely done.   The problem of calculating ICCCRT 
is even more acute because it requires a large number of clusters and is probably different 
depending on the nature of the cluster, as well as on the other parameters. 
 It is interesting to compare the psychometric statistics (see Table 4).  In every case, an 
instrument with smaller SD will result in a larger value of the statistic, because SD is in the 
denominator of each statistic.  Note, however, that Reliability is also strongly related to the 
variance among people (s2z), as is well known.  If s2z is large relative to SD (perhaps in a 
general population), then Reliability will approach 1, and if it is small (perhaps in patients 
recovering from the same surgical procedure), Reliability will be primarily a function of SD, or 
the instrument.  Reliability is thus not the property only of the instrument, but also of the 
norming sample.   Effect Size is a function of the instrument, the population, and also ∆, which 
can vary substantially as noted above.  Responsiveness is not related to s2z, but is related to ∆, 
SD2, and also to the variance of the secular trend over time.  An evaluation setting with 
substantial variability in how subjects changed over time would show less Responsiveness than 
one in which all people moved in the same direction by about the same amount.  Finally, ICC is 
a function of all of these factors plus variation in the type of cluster; the ICC is likely to be 
higher in interacting units such as families and workplaces than in counties and states.  Published 
values of the psychometric statistics are clearly most valuable when calculated in a similar 
context to the new planned investigation. 
 The calculations above give some guidance about the sample sizes needed to obtain good 
estimates of the psychometric statistics.  Once the data have been collected, a bootstrap approach 
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could be used to provide approximate confidence intervals for the estimate, as suggested by Feng 
and Grizzle. 25 
 
Limitations. These findings should not depend very much on the exact form of the model we 
assumed.  The model did not include a person-level error term, but it would have cancelled out in 
the analysis of change that was assumed.  We assumed that the error terms were independent of  
Z and of one another, to make the calculations more straightforward.   We could have made the 
treatment effect random instead of fixed.  None of these are likely to have affected the results 
much.  We let Y be an unbiased estimate of Z.  We could alternatively have let E(Y) = a+bZ, 
since a and b would have disappeared in the calculation of the psychometric statistics.  If Y was 
a non-linear function of Z, results would have been similar in kind but would not be exact.  We 
examined a reasonable range of model parameters.   In the simulations we estimated the value of 
Delta separately from each sample.  If we had used a fixed value for Delta, the variances of 
estimated effect size and responsiveness would have been lower.     
  
Conclusion.   In RCTs and CRTs, there are situations in which the best instrument in terms of 
psychometric qualities is not the most cost-effective instrument for the study at hand.  Efforts to 
decrease the complexity of current instruments, such as the SF-36, are likely to pay off in many 
situations. 
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 Table 1 
 The Models for Z (Truth) and Y (Instrument) 
         
   Z = TRUE STATE 
 
 
Z0         N(µz = 50,  sz  = 10 ) 
Z1         Z0          
Z2 Z1         +  N(µtrend  =1, strend  =1)  +  ∆= Treatment effect = 3 
   Secular Trend   Treatment 
 
   Y = INSTRUMENT 
  
y0         Z0         + ε  ;   ε  ~ N(M, SD) M=0; SD = 0,1,2,5,10 
y1         Z1         +  ε  ;   ε   ~ N(M,SD) 
y2 Z2         +  ε  ;   ε  ~ N(M, SD)  
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 Table 2 
 
 Distributions of True and Measured Health Variables 
 
Variable Mean Variance 
Z0 µz =  50 s2z =  100 
Z1 µz =  50 s2z =  100 
Z2 µz +µtrend            = 51 (control) 
µz +µtrend + ∆ = 54 (treatment)  
s2 z + s2trend =  101 
Y0 µz =   50 s2z + SD2 = 100+SD2 
Y1 µz =   50 s2z + SD2 = 100+SD2 
Y2 µz +µtrend            = 51 (control) 
µz +µtrend +  ∆ = 54 (treatment)  
s2z +s2 trend+ SD2 =101+SD2  
Y2 - Y1 µtrend               = 1  (control) 
µtrend + ∆   = 4  (treatment) 
s2trend+ 2*SD2 =1+ 2*SD2  
* The distribution of the Y’s is unconditional; that is, not conditioned on Z. 
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Table 3 
 
 Correlations among True and Measured Health Variables 
 
 
SD R2yz ryz R2yy ryy 
2.29 .950 .975 .902 .950 
3.33 .900 .949 .810 .900 
5.00 .800 .894 .640 .800 
6.55 .700 .837 .490 .700 
10.00 .500 .707 .250 .500 
17.30 .250 .500 .063 .250 
       
          
R2yz is the correlation between the true (Z) and measured (Y) values at a particular time. 
 
R2yy is the correlation between Y0 and Y1. 
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 Table 4 
             
 True Psychometric Characteristics* of the Instrument Y 
 As a Function of Measurement Error (SD)   
 
  Reliability Effect Size Responsive- 
ness 
 
N per group 
for 80% 
power 
ICC for Change 
from T1 to T2 
 
 
 
 
σ
σ
z
z SD
2
2 2+
∆
σ z SD2 2+
∆
σ trend SD2 22+ * )
2 196 84 2
2
* ( . . )
Re
+
sponsiveness
σ
σ σ
C
C trend SD
2
2 2 22+ + *  
0.00 1.0 .300  3.00 “3.5" .5000 
2.29 .95 .292 .89     22 .0800 
3.33 .90 .284 .62     42 .0414 
5.00 .80 .268 .42     91 .0192 
6.55 .70 .250 .32   153 .0114 
10.00 .50 .212 .21   352 .0050 
17.30 .25 .151 .12 1046 .0017 
   
*  Assumes sz =10, strend =1, ∆= 3, and  sC = 1. 
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 Table 5 
 CRT Sample sizes needed per cluster to achieve 80% power 
 by ICC, Reliability, and C (# clusters/tx group)*  **  
  
ICC Reliability  \  C 
(#Clusters/tx grp) 
C=2 C=5 C=10 C=15 C=20 
.01 .25    310 124 
 .50  1156 65 34 23 
 .70  65 20 12 9 
 .80  30 11 7 5 
 .90 297 12 5 3 2 
 .95 59 6 2 1 1 
.025 .25      
 .50    70 35 
 .70   34 15 10 
 .80  57 15 8 5 
 .90  14 6 3 2 
 .95 668 6 3 1 1 
.05 .25      
 .50     605 
 .70   154 25 14 
 .80   21 10 6 
 .90  24 6 3 2 
 .95  7 3 2 1 
   
* Note: s2C is different for each line; s2C = ICC/(1-ICC)*[1 + 200*(1-Reliability)/Reliability], 
assuming sz =10  and strend=1. 
 
**A blank cell indicates that it is not possible to achieve 80% power with the specified 
configuration. 
http://biostats.bepress.com/uwbiostat/paper284
  
28 
 Table 6 
 Descriptive and Psychometric Statistics from the Lido Study 
 
  5-Item Score (MHI-5) Single Item Score 
baseline mean 43.3 1.23
baseline s.d. 18.4 .42
Corr (baseline, 6 weeks) .51 .38
Reliability .48 .37
Effect Size 1.06 .83
Responsiveness .94 .74
 
Cost (length) 6 2
Sample Size Needed (N) 18 29
Total cost ~ Cost * N 108 58
 
s2C of change among 
communities  
13.99 .0037
ICC of change .025 .012
ICC of baseline Y .017 .066
ICC of 9 month Y .042 .061
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 Figure 1 
 Distribution of Reliability Estimates, N=20, True Reliability = .80 
 
    
 
 
Estimated Reliability
.950
.900
.850
.800
.750
.700
.650
.600
.550
.500
.450
151 Estimates of Reliability (true = .80)
Based on 20 persons per sample
20
10
0
Std. Dev = .09  
Mean = .796
N = 151.00
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